Adicet Bio, Inc.: research and development expense
Research and development expense for Adicet Bio, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Adicet Bio, Inc. financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 99,127,000 | USD | 2026-03-12 | 10-K · 0001720580-26-000008 |
| 2024-01-01 | 2024-12-31 | 99,323,000 | USD | 2026-03-12 | 10-K · 0001720580-26-000008 |
| 2023-01-01 | 2023-12-31 | 106,043,000 | USD | 2025-03-06 | 10-K · 0000950170-25-034587 |
| 2022-01-01 | 2022-12-31 | 71,246,000 | USD | 2024-03-19 | 10-K · 0000950170-24-033482 |
| 2021-01-01 | 2021-12-31 | 48,943,000 | USD | 2023-03-15 | 10-K · 0000950170-23-008130 |
| 2020-01-01 | 2020-12-31 | 34,334,000 | USD | 2022-03-15 | 10-K · 0000950170-22-003753 |
| 2019-01-01 | 2019-12-31 | 23,691,000 | USD | 2021-03-12 | 10-K · 0001564590-21-012664 |
| 2018-01-01 | 2018-12-31 | 14,717,000 | USD | 2021-03-12 | 10-K · 0001564590-21-012664 |
| 2017-01-01 | 2017-12-31 | 16,839,000 | USD | 2020-03-12 | 10-K · 0001564590-20-010474 |
Related financial histories
- Adicet Bio, Inc.: total assets
- Adicet Bio, Inc.: total liabilities
- Adicet Bio, Inc.: stockholders equity
- Adicet Bio, Inc.: cash and cash equivalents
- Adicet Bio, Inc.: net income or loss
- Adicet Bio, Inc.: operating cash flow
- Adicet Bio, Inc.: capital expenditure payments
- Adicet Bio, Inc.: financing cash flow
- Adicet Bio, Inc.: investing cash flow
- Adicet Bio, Inc.: retained earnings or deficit
- Adicet Bio, Inc.: basic weighted-average shares
- Adicet Bio, Inc.: diluted weighted-average shares
- Adicet Bio, Inc.: basic earnings per share
- Adicet Bio, Inc.: diluted earnings per share
- Adicet Bio, Inc.: income tax expense or benefit
- Adicet Bio, Inc.: net property, plant and equipment
- Adicet Bio, Inc.: share-based compensation expense
- Adicet Bio, Inc.: operating income or loss
- Adicet Bio, Inc.: current assets
- Adicet Bio, Inc.: interest expense
- Adicet Bio, Inc.: current liabilities
- Adicet Bio, Inc.: current accounts payable
- Adicet Bio, Inc.: goodwill carrying amount
- Adicet Bio, Inc.: operating expenses
Inspect the source
- Entity
- Adicet Bio, Inc. / CIK 0001720580
- Captured
- 2026-09-21T17:24:52.699Z
- SEC response SHA-256
d25e8106f45b63db351597e725e43aa53c3f7a99240804322c6e0718e6bdbb55
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001720580.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))